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Abstract
Purpose Pituitary metastases (PM) are uncommon findings and are mainly derived from breast and lung cancers. No 
extensive review of PM from neuroendocrine neoplasms (NENs) is on record. Here we describe a clinical case of PM from 
pancreatic NEN and review the clinical features of PM from NENs reported in the literature.
Methods A case of PM from a pancreatic NEN followed at our institution is described. We also reviewed the 43 cases of 
PM from NENs reported in the literature.
Results A 59-year old female patient, previously submitted to duodeno-cephalo-pancreasectomy for a well-differentiated 
pancreatic NEN, with known hepatic metastases, underwent a 68 Ga-DOTATOC PET/CT that revealed an uptake in the 
pituitary gland. A subsequent MRI displayed a pituitary lesion, with suprasellar extension. After a hormonal and genetic 
diagnostic workup that excluded the diagnosis of MEN 1, the worsening of headache and visual impairment and the growth of 
the lesion lead to its surgical removal. A pituitary localization of the pancreatic NEN was identified. Regarding the published 
cases of PM from NENs, the most common tumour type was small cell lung cancer (SCLC), accounting for nearly half of the 
cases, followed by bronchial and pancreatic well differentiated NENs. The most frequent symptom was a variable degree of 
visual impairment, while headache was reported in half of the cases. Partial or total anterior hypopituitarism was present in 
approximately three quarters of the cases, while diabetes insipidus was less common. The most frequent treatment for PM 
was surgical resection, followed by radiotherapy and chemotherapy. The clinical outcome was in line with previous reports 
of PM from solid tumours, with a median survival of 14 months. Surgery of PM was associated with prolonged survival.
Conclusions PM from NENs have clinical features similar to metastases derived from other solid tumours, albeit the involve-
ment of the anterior pituitary seems more frequent; a thorough pituitary hormonal evaluation is mandatory, after focused 
radiological studies, particularly if a surgical approach is considered. The optimal management of PM remains disputed 
and seems mainly driven by the aggressiveness of the primary tumour and the presence of symptoms. In well-differentiated 
NENs, particularly in the case of symptomatic PM, surgical removal may be a reasonable approach.
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Introduction
Pituitary metastases (PM) are uncommon findings and their 
reported incidence is variable. Being often asymptomatic, 
their prevalence is higher in autopsy series [1]; moreover, 
they can be incidentally found during imaging workup in 
patients with advanced neoplastic disease [2]. Given the 
absence of pathognomonic radiological or clinical find-
ings and the risk of hormonal disarrangement derived from 
pituitary tissue invasion, differentiating PM from pituitary 
adenomas can be difficult [2, 3]. Breast and lung cancer are 
the tumours that most frequently metastasize to the pituitary 
gland [1]. However, PM derived from neuroendocrine neo-
plasms (NENs) have been increasingly reported especially 
in the last decades [4–6]. While extensive reviews regarding 
clinical presentations and management of PM from several 
solid tumours have already been published [1, 3], no studies 
specifically regarding PM from NENs are on record. Here 
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we reported the case of a PM from a pancreatic NEN man-
aged at our centre and we reviewed the published literature 
regarding PM from NENs (both single case reports and case 
series), describing their main clinical, diagnostic and thera-
peutic features.
Case presentation
We report the case of a 59-years old female patient who was 
followed-up at our tertiary centre for metastatic pancreatic 
NEN. The tumour was incidentally detected in 2008 by an 
abdominal CT scan and, therefore, the patient underwent 
duodenocephalopancreasectomy with lymphadenectomy. 
The pathology report was consistent with a G1 well-differ-
entiated pancreatic neuroendocrine tumour (NET) (Ki-67 
index: 4%) with metastasis in 1 out of 32 excised lymph 
nodes. Tumour cells did not express pancreatic hormones 
but intense and diffuse immunoreactivity for the general 
neuroendocrine marker chromogranin A reactivity was 
observed. In addition, inhibin expression was detected, as 
rarely occurring in NETs with clear cell changes [7] (see 
Fig. 1). Given the absence of residual disease, no adjuvant 
therapy with somatostatin analogues was administered at 
that time.
In 2017, after 9 years of complete remission, the tumour 
relapsed and a small lesion in the liver with several enlarged 
abdominal lymph nodes was detected by means of MRI. 
At that time, the patient refused therapy with somatostatin 
analogues. In June 2018, a restaging 68 Ga-DOTATOC PET/
CT confirmed the presence of the known metastatic lesions, 
apparently stable in size after 11 months, and revealed a 
slightly increased accumulation of the radiotracer in the 
pituitary gland. At the time, the patient complained about 
the onset of bilateral galactorrhea but denied any headache, 
polyuria or polydipsia. The subsequent MRI scan described 
the presence of a large (20-mm in its largest diameter) pitui-
tary lesion, that was supposed to be a pituitary adenoma. In 
particular, the lesion had a suprasellar extension with com-
pression of the optic chiasm and the suprasellar cistern, and 
displacement of the pituitary stalk. It was dyshomogene-
ously hypointense and hyperintense in T1-and T2-weighted 
sequences, respectively, and showed a strong and premature 
contrast enhancement (see Fig. 2). The visual field campim-
etry showed bitemporal impairment. The biochemical and 
hormonal tests (see Table 1) demonstrated normal levels of 
sodium, potassium, calcium, parathyroid hormone (PTH), 
gonadotropins (considering the postmenopausal condition) 
and IGF-1 by age; in contrast, prolactin was moderately 
increased and the evaluation of the pituitary-thyroid axis 
was consistent with secondary hypothyroidism. The normal 
response of cortisol to 1 µg Cosyntropin ruled out a pos-
sible secondary adrenal insufficiency. We started treatment 
with cabergoline and levothyroxine and galactorrhea subse-
quently disappeared. A genetic test for multiple endocrine 
neoplasia (MEN) 1 syndrome was performed, but mutations 
in the MEN1 gene were ruled out. 
Given the gradual onset of headache, the worsening of the 
visual impairment, and the radiological evidence of progres-
sive enlargement of the pituitary mass at a subsequent MRI 
scan after 6 months, a 3D extended endoscopic endonasal 
approach to sellar and suprasellar region was performed 
[8] in June 2019. Postoperative clinical course was charac-
terized by the development of diabetes insipidus (DI) that 
required therapy with desmopressin. The histopathological 
examination of the surgical specimen was consistent with a 
pituitary localization of a well-differentiated NEN, but the 
differential diagnosis of a pituitary adenoma from a meta-
static NET was not possible on morphological ground, only 
(see Fig. 1). Immunohistochemical stainings for pituitary 
hormones (prolactin, ACTH, GH, FSH, LH, TSH) as well 
as those for pituitary markers TPIT, Pit1 and GATA3 were 
all negative. Despite the pituitary tumour did not contain 
clear cells, inhibin immunostaining was diffusely positive, 
with a pattern similar to that of the primary pancreatic NET. 
The proliferative index (assessed by the MIB1 monoclonal 
antibody to Ki-67) was 8%, almost double than that of the 
primary pancreatic NET. Pathology of the resected tumour 
was eventually interpreted as a PM of the pancreatic G2 
NET resected 11 years earlier.
Fig. 1  Pancreatic NEN progressed with metastasis to the pituitary 
gland. a microscopic features of the pancreatic NEN with an orga-
noid growth made of occasionally clear cells with scant atypias; b the 
ki-67 proliferative index was low (1%) and the tumour was graded 
G1; c, d chromogranin A and synaptophysin were diffusely positive; 
e the tumour was also strongly reactive for inhibin. The resected PM 
had a similar architecture (f), but tumour cells had no clear cyto-
plasm, and rather showed an increased ki-67 proliferative activity 
(8%) g tumour cells also shared the immunoprofile of the primary 
pancreatic tumour, with diffuse reactivity for chromogranin A (h), 
synaptophysin (i) and inhibin (l). NEN neuroendocrine neoplasm, PM 
pituitary metastasis
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The post-surgical hormonal tests (see Table 1) confirmed 
the secondary hypothyroidism and revealed the onset of sec-
ondary hypocortisolism. Hence, glucocorticoid hormonal 
replacement therapy was added to the levothyroxine and 
desmopressin treatment.
Given the progression of the liver disease, therapy with 
monthly octreotide was started after surgery. Three and 
six months after surgery, follow-up MRI scans showed 
no sign of residual tissue in the sellar region. Unfortu-
nately, no improvement was demonstrated at the visual 
field campimetry evaluation. One year after surgery, the 
patient underwent restaging scans with both 68 Ga- and 
18F-FDG PET/CT, which showed no uptake in the pituitary 
region and stability of the known liver and lymph node 
metastases.
The patient is currently in good clinical conditions and 
pituitary deficiencies are well controlled by replacement 
therapy two years after pituitary surgery and 13 years after 
pancreatic NET resection. Her therapy continues with 
monthly octreotide with good tolerance.
Fig. 2  Coronal (left) and sagit-
tal (right) pre-operative MRI 
scans showing the inhomogene-
ous sellar lesion with supra-
sellar extension. MRI magnetic 
resonance imaging
Table 1  Hormonal and 




a during replacement therapy with levothyroxine
b after 24 h from the last dose of corticosteroid replacement therapy
c during replacement therapy with desmopressin






TSH, µUI/ml 0.27–4.20 2.64  < 0.005  < 0.005
fT4, pg/ml 9.3–17.0 8.6 8.3a 11.3a
fT3, pg/ml 2.6–4.4 – 1.5a 2.1a
ACTH, pg/ml  < 46 17  < 5  < 5
Basal cortisol, µg/l 62–194 122 8.1 1.9b
Stimulated* cortisol, µg/l  > 180 221 – –
Prolactin, ng/ml 4.8–23.3 119  < 0.1 –
IGF-1, ng/ml 65–320 83 – –
Sodium, mmol/l 135–145 144 149 140
Potassium, mmol/l 3.5–5.0 4.6 5.3 4.6
pOsm, mOsm/Kg 278–305 301 300c 293c
uOsm, mOsm/Kg 50–1400 112 232c 218c
PTH, pg/ml 15–57 48 – –
Calcium, mmol/l 2.2–2.6 2.25 – –
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Literature review
We thoroughly reviewed all cases of PM from NENs avail-
able from the literature. We searched PubMed and MED-
LINE database using the following, variously combined, 
keywords: “pituitary metastasis”, “sellar metastasis”, 
“neuroendocrine tumour”, “neuroendocrine neoplasm”, 
“neuroendocrine carcinoma”, “small cell lung cancer”, 
“carcinoid tumour”. A review of the abstract of each 
retrieved study was then carried out. Only publications 
with abstract and/or full text in English language were 
included. Studies in which the histological diagnosis of 
the primary NEN and of PM was lacking were excluded. 
Figure 3 shows the process of identification, screening and 
exclusion of the retrieved articles.
For each case, the following data were gathered: year of 
publication, gender and age of the patient, primary tumour 
and PM histology, known metastatic disease before dis-
covery of PM, presenting signs and symptoms, and treat-
ment of PM. In those PM who were not surgically treated, 
histology of PM was obtained through either autopsy or 
biopsy of the lesion. When available, also hormonal alter-
ations, radiological features at the time of diagnosis as 
well as survival data were collected and analysed. Survival 
analysis was performed using the Kaplan–Meier method 
and survival distribution comparison was done using the 
logrank test.
Finally, 42 reported cases of pituitary masses histo-
pathologically consistent with a pituitary localization of 
NENs were found between 1984 and 2020 [4–6, 9–46]; 
by adding our patient, a total of 43 cases were analysed. 
The relevant data are summarized in Table 2. The average 
Fig. 3  Flowchart for the literature review
Table 2  Demographic, pathological, clinical, hormonal, imaging and 
therapeutic characteristics of the 43 reported cases of PM from NENs
PM pituitary metastases, NEN neuroendocrine neoplasm, SCLC small 
cell lung cancer, MTC medullary thyroid cancer, LCNEC large cell 
neuroendocrine carcinoma, DI diabetes insipidus, PRRT peptide 
receptor radionuclide therapy, IQR interquartile range
Total number of cases n = 43 (%)
Sex n = 43 (%)
 M 19 (44)
 F 24 (56)
Median age (y) 58
Primary NEN histology n = 43 (%)
 SCLC 21 (49)
 Atypical lung carcinoid 6 (14)
 Pancreatic NEN 4 (9)
 MTC 3 (7)
 Thymic carcinoid 2 (5)
 Unknown primary NEN 2 (5)
 Breast NEN 2 (5)
 Ileal NEN 1 (2)
 Merkel cell carcinoma 1 (2)
 Lung LCNEC 1 (2)
PM as first manifestations of NEN 23 (53)
Clinical presentation n = 41 (%)
 Visual field deficit 27 (66)
 Headache 20 (49)
 Constitutional symptoms (asthenia, weight loss) 18 (44)
 Other ocular symptoms (diplopia, blurred vision) 18 (44)
 Ocular palsy 9 (22)
 Other neurological symptoms (gait disturbance, confu-
sion, memory loss)
6 (15)
Hormonal alterations n = 37 (%)
 Hypopituitarism (deficit of at least one pituitary axis) 27 (73)
 Hyperprolactinemia 21 (57)
 Gonadotropins deficit 19 (51)
 ACTH deficit 15 (40)
 TSH deficit 15 (40)
 DI 13 (35)
 Panhypopituitarism (complete anterior pituitary defi-
cit + DI)
6 (16)
Imaging characteristics n = 36 (%)
 Suprasellar extension 30 (83)
 Compression/displacement of pituitary stalk 20 (56)
 Bone erosion 9 (25)
 Invasion of cavernous sinus 7 (19)
 Involvement of other brain structures 7 (19)
 Thickening/involvement of pituitary stalk 4 (11)





Median survival [months, (95% CI)] 14 (9–21)
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age of patients at PM diagnosis was 58  years (range 
23–82 years) with a slight female predominance (56%).
Small cell lung cancer (SCLC) was the most represented 
primary NEN (49%), followed by atypical bronchial car-
cinoid (14%), pancreatic well-differentiated NENs (9%), 
and medullary thyroid cancer (MTC; 7%). The primary 
site of the remaining cases is listed in Table 2. Only one 
patient (with metastatic MTC) had a definitive diagnosis 
of multiple endocrine neoplasia (MEN) 2B syndrome [32]. 
No patients with MEN 1 syndrome were present among the 
cases retrieved.
PM appeared as a manifestation of an already known 
metastatic disease in only 23% of patients. In the remaining 
cases, mainly consisting of SCLC, PM was the first presenta-
tion of a neoplastic disease of unknown primary.
Hormonal data were available for 86% (37/43) of patients. 
Hypopituitarism (defined as a deficit of at least one of the 
adenohypophysis hormonal axes) was the most common 
endocrine alteration, being present in 73% of patients. 
Hyperprolactinemia was found in 57% of cases. The gonadal 
axis was involved in nearly half of patients (51%), while the 
corticotroph and the thyrotroph axes were less frequently 
impaired (both 40%). DI was reported in approximately 
one third of the patients (35%). Panhypopituitarism (i.e. the 
presence of complete anterior pituitary deficit and DI) was 
present in 16% of cases only.
A paraneoplastic syndrome related to the ectopic secre-
tion of pituitary peptides from NEN cells was detected in 
six cases (Cushing syndrome in four and acromegaly in two 
patients) [13, 16, 21, 28, 29, 46]. Interestingly, in five other 
cases, PM developed within a pituitary adenoma (two non-
functioning adenomas, one prolactinoma, one GH-secreting 
and one ACTH-secreting adenoma) [12, 30, 32, 34, 43].
Data on neurological or ocular symptoms at PM diagnosis 
were available for 95% (41/43) patients. Visual alterations 
were the most frequent clinical manifestation, being present 
in all but six patients. Specifically, visual field impairment 
was present in 66% of patients, 44% reported diplopia or 
blurred vision, and 22% had paralysis of at least one ocu-
lomotor nerve. Headache was reported in 49% of patients.
Relevant radiological features detected by MRI and/or 
CT scan were reported in 84% (36/43) patients. Most of 
them (83%) had a suprasellar extension; a displacement 
and/or a compression of the optic chiasm was radiologi-
cally found in more than half cases (56%). Bone erosion 
was observed in one case, while only 19% showed an inva-
sion of the cavernous sinus. Four radiological reports [11, 
19, 21, 28] described a thickening or an involvement of the 
pituitary stalk. In a minority of patients, the authors reported 
the involvement of other encephalic structures, such as the 
compression of the third ventricle (n = 4) [22, 25, 36, 39], 
of the optic nerve (n = 2) [13, 25] or the extension into the 
prepontine and premesencephalic cisterns (n = 1) [22].
When available, the signal intensity of PM on the 
T1-weighted and T2-weighted sequences of the MRI scan 
was variable among the reports. In two cases, the loss of 
the expected T1-hyperintense signal of the posterior lobe 
was observed [11, 19]. After paramagnetic contrast injec-
tion, MRI scan demonstrated a homogeneous enhance-
ment for some lesions, while an inhomogeneous enhance-
ment was described by other studies. The pituitary mass 
was associated to other central nervous system (CNS) 
metastatic lesions in 17% of cases. Moreover, a rapid PM 
growth was reported in three patients who performed two 
MRI scans at a close time interval [6, 36, 41]. Two PM 
appeared calcified [6, 40] and one caused a fibrotic reac-
tion around the sella turcica [23].
Nearly three quarters (74%) of patients underwent sur-
gical resection of PM, mainly through a trans-sphenoidal 
approach; a craniotomic approach was performed only 
in three patients (in all cases during the 1980s) and one 
patient had a trans-ciliary approach. Among patients not 
surgically treated, but having a histological diagnosis 
based on the biopsy, all but one underwent radiotherapy 
(RT) or chemotherapy (CT) treatment regimens. Overall, 
RT and CT were employed in 51% and 44% of patients, 
respectively. Only in two patients peptide receptor radio-
nuclide therapy (PRRT) was used in combination with 
other treatments.
Regarding clinical, hormonal and/or local improvement 
after therapy of PM, data were lacking for the majority 
of patients. Among the cases with available data on neu-
rological outcome (30%, 13/43), 77% showed clinical 
improvement of neurological symptoms; among them, 
almost all the patients were surgically treated with only 
one case that did not undergo surgery, but was treated with 
RT and CT. Regarding ocular symptoms (data available for 
53% of patients, 23/43), some improvement after therapy 
was seen in 61% of patients. All but two of these patients 
had undergone surgical resection of PM and the majority 
was also treated with RT. Given the lack of data, it was 
not possible to carry out an analysis regarding hormonal 
improvement after PM therapy.
Survival data were available for 70% of patients (30/43). 
The median survival from PM diagnosis was 14 months 
(95% CI 9–21 months); five patients survived more than 
18 months. Surgery was associated with prolonged sur-
vival (see Fig. 4): patients who underwent surgical resec-
tion of PM had a median survival of 18 months (95% CI 
14.0–26.0), compared to 9 months (95% CI 4.0–11.0) for 
patients that were not surgically treated (p = 0.09). No 
difference in survival was noted in patients with SCLC 
compared with patients with NENs from other histology.
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Discussion
We presented a rare case of PM from a pancreatic NET, 
which gives us the opportunity to speculate on the tools for 
distinguishing this lesion from a pituitary adenoma and to 
revise the literature on metastatic localizations of NENs 
in the pituitary gland.
PM are rare findings, even in patients with an advanced 
neoplastic disease. In general, approximately 5% of 
patients with a known history of malignancy are thought 
to have a latent PM [47], with the highest percentages in 
patients with breast cancer [1, 48, 49]. The abundant blood 
supply of the pituitary gland may facilitate hematogenic 
metastatic spreading and seeding [50]. As observed in five 
of the cases included in this review, PM can even develop 
inside a pituitary adenoma (so called “collision tumours”) 
that could be hormonally active [32].
Compared to the published reviews on PM from NENs 
[4–6], the present review on 43 cases (42 from the litera-
ture and one presented in this review) by covering a time 
span of 36 years, allows to better evaluate the clinical fea-
tures of patients suffering from NEN-derived PM.
Among the cases of PM from NENs, the most common 
primary tumour was SCLC in line with recently published 
studies [5, 6]. This finding is somewhat expected, given 
the aggressive clinical behaviour of this type of tumour 
and its high metastatic potential, especially to the CNS 
[51]. In previous studies regarding PM from any primary 
tumour location, they represented the first manifestation 
of neoplastic disease in approximately 20–30% of cases 
[1, 38, 52, 53]. Conversely, in the population analysed 
in this review, PM was the first manifestation of malig-
nancy in the majority of patients. Most of these cases were 
represented by SCLC, notoriously characterized by a rapid 
metastatic spreading.
Regarding symptoms, prevalence of DI and hyperpro-
lactinemia in patients with PM from NEN appears to be 
in line with other reports regarding PM from other solid 
tumours [38, 52, 53]. Conversely, in patients with PM 
from NEN, hypopituitarism, in comparison with recent 
large reviews in PM from solid tumours [1, 38, 53], was a 
more common alteration; in this review, the most involved 
pituitary axis was the gonadal one, followed by secondary 
hypoadrenalism and hypothyroidism. These findings are 
consistent with previous observations, although only a small 
number of patients were tested for hypogonadism in those 
series [52].
The diagnosis and clinical management of PM, espe-
cially from NENs, can be challenging also due to the pos-
sible coexistence of paraneoplastic syndromes, as seen in 
this review. Moreover, when evaluating a sellar mass in a 
patient with a known NEN, the possibility of a diagnosis 
of MEN syndrome should be taken into consideration. The 
currently reported case had only moderately increased PRL 
levels associated with secondary hypothyroidism. A treat-
ment with cabergoline and levothyroxine was started and 
mutations in the MEN1 gene were ruled out.
Also the prevalence of visual alterations and cranial nerve 
palsy were similar in our analysis compared with previous 
reports [37, 38, 52, 54]. Given their rarity in pituitary adeno-
mas, some Authors proposed that in the presence of a pitui-
tary mass, either DI or cranial nerve palsies should favour a 
diagnosis of PM rather than pituitary adenoma, especially if 
rapidly progressive and affecting patients older than 50 years 
[1].
MRI is the gold standard for the study of sellar lesions. 
Although several findings might point toward a diagnosis 
of PM, radiological techniques are usually unable to clearly 
distinguish between PM and pituitary adenomas [5]. Moreo-
ver, the published reports did not always include a detailed 
neuroimaging description, limiting the definition of a spe-
cific radiological pattern for NEN-derived PM as opposed 
to pituitary adenomas.
In previous reports, PM have been described as dumb-
bell-shaped intrasellar and suprasellar lesions, with a clear 
indentation at the level of the diaphragma sellae on sagittal 
images. However, this presentation might also be seen in 
case of benign tumours [37, 54].
According to other studies about PM, MRI generally 
revealed an isointense or hypointense sellar mass on 
T1-weighted and hyperintense on T2-weighted images, 
with homogeneous enhancement after gadolinium. How-
ever, neither of these findings has been demonstrated to be 
highly specific for PM [54]. In this series, the signal inten-
sity of the pituitary lesion on the MRI did not help in the 
differential diagnosis of the pituitary mass. Some lesions 
Fig. 4  Kaplan–Meier survival analysis comparing outcomes between 
surgically-treated (dashed line) versus non surgically-treated (solid 
line) patients with PM. PM pituitary metastases
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were characterized by inhomogeneous enhancement, prob-
ably as a result of intralesional haemorrhage or necrosis. 
Moreover, the loss of the posterior lobe brightness has 
been described in two of the reported cases, maybe due to 
tumour infiltration, similarly to what has been anecdotally 
reported in literature [37].
The suprasellar extension of the pituitary mass was 
reported in the majority of the cases included in our 
review, in accordance with the available data for PM 
from other tumours [3]. Many of the selected cases also 
described an involvement of the optic chiasm, with sub-
sequent relevant clinical implications, as observed in our 
patient.
Being a malignant lesion, tumour growth rate of PM is 
expected to be higher than for pituitary adenomas [3], also 
in well-differentiated NENs. Indeed, a rapid growth was 
reported also among the cases in the current review (includ-
ing our patient), when serial MRIs were performed at short 
temporal distance. Interestingly, in our case, the Ki67 pro-
liferation index was higher in the PM than in the primary 
pancreatic NET. This finding may reflect a tendency of the 
tumour to progress towards a higher grade, along time, and 
may have a prognostic meaning [55].
Overall, the differential diagnosis of a sellar mass should 
include the possibility of PM, especially in case of an 
enhancing, rapidly-growing suprasellar mass with signs of 
neurological or hormonal impairment (hypopituitarism, dia-
betes insipidus, cranial nerve palsy) in a patient aged more 
than 50 years [56, 57].
There are no specific recommendations for the treatment 
of sellar masses suspicious for PM. Given the frequent 
suprasellar extension and local invasiveness, a complete 
surgical excision is frequently not achievable [58]. None-
theless, surgical treatment of PM (mainly through a trans-
sphenoidal route) could have a role in symptoms palliation 
[59, 60]. No significant improvement in survival outcomes 
has been reported after surgery in some cohorts [58, 61], 
probably because surgical indications had been considered 
only for rapidly growing and symptomatic PM from more 
aggressive tumours.
In this review, we found that surgical resection of PM 
was associated with an improvement in survival. By analys-
ing the limited data of the low number of cases retrieved, it 
appears that this survival advantage was not related to differ-
ences in patients and disease characteristics between the two 
groups. Nonetheless, it could be postulated that localized or 
oligometastatic disease and general good clinical condition 
may support a more aggressive choice of treatment, there-
fore favouring the surgical approach and a better survival. 
Although the small number of cases and the retrospective 
nature of the analysis are clear limits of this analysis, this 
finding could make surgery a reasonable approach not only 
for symptoms palliation but also for prolonging survival.
Regarding histopathology, high grade neuroendocrine 
carcinomas of small and large cells can easily be classified, 
but the correct distinction of a pituitary adenoma from a 
metastatic well-differentiated NEN is challenging, since the 
morphological features of these neoplasms are largely over-
lapping in the various locations. In such context, a carefully 
selected immunohistochemical panel is crucial for a good 
differential diagnosis. Specifically, an algorithmic approach 
is indicated including, as a first step, pituitary-specific tran-
scription factors (Pit1, TPIT, SF1 and GATA3), as well as 
TTF1 (for lung NENs and MTC) and CDX2 (for intestinal 
NENs). Subsequently, the refinement of the diagnosis may 
benefit of immunostainings for site- and cell type-specific 
hormonal products and other markers [62]. In the current 
case, pituitary-related transcription factors and pituitary 
hormones were not expressed and this was in favour of a 
metastatic localization of the known pancreatic NET. The 
rare expression of inhibin, generally associated to NETs 
with clear cell changes [7] was observed also in the pitui-
tary tumour, further supporting the metastatic nature of the 
lesion.
Among the therapeutic strategies for PM, RT is another 
valuable option, usually employed when surgery is not indi-
cated or in the post-operative setting. A recent systematic 
review showed significant survival advantage in patients 
treated with RT, in particular with the stereotactic technique 
[61].
In our series, only two patients with PM from NENs have 
been treated with PRRT [5, 23], with a substantial radiologi-
cal and clinical response in one of them [5]. PRRT is a novel 
treatment option shown to produce substantial responses in 
patients with metastatic well-differentiated NENs associated 
to a significant disease burden [63]. While no study specifi-
cally focused on the response of PM to PRRT was designed, 
some reports regarding the use of PRRT in the setting of 
aggressive pituitary tumours are available [64].
Despite the various treatment options available, PM 
from solid tumours remains a condition with a poor prog-
nosis: previous studies showed a median survival for PM 
of 13.6 months [38]. Data from this review, with a median 
survival of 14 months, are in line with previous reports on 
PM from all solid tumours.
In conclusion, PM is an uncommon manifestation of 
NENs, and it should be suspected in the presence of hormo-
nal disarrangement and/or ocular or neurological symptoms 
in patients with previous diagnosis of NEN. Their features 
are mainly similar to those of PM deriving from other solid 
tumours. However, PM from NENs seem to show a more 
frequent involvement of the anterior pituitary rather than the 
neurohypophysis. Therefore, a thorough hormonal evalua-
tion, including all the pituitary axes, is essential; in particu-
lar, secondary adrenal insufficiency must be ruled out given 
its life-threatening risk. The differential diagnosis from 
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pituitary adenoma is not easy, considering the overlapping 
morphology with, at least, well-differentiated NEN; thus, 
a proper use of specific histopathologic markers is needed. 
Clearly, the high growth rate and the presence of concomi-
tant brain lesions should raise suspicion of PM. Although 
reported survival outcomes remain poor, surgical resection 
may be considered in selected patients.
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